rs10181656 — STAT4

STAT4 Intron 3 — Risk Haplotype Tagging Variant

STAT4 (Signal Transducer and Activator of Transcription 4) is a transcription factor that sits at the core of the IL-12 and interferon-alpha signaling cascade. When immune cells encounter pathogens or self-antigens, IL-12 and type I interferons activate JAK kinases, which phosphorylate STAT4, driving it into the nucleus where it triggers Th1 differentiation, NK cell activation, and IFN-gamma production¹¹ Th1 differentiation, NK cell activation, and IFN-gamma production
The STAT4 pathway is also the molecular target of JAK inhibitors used in rheumatoid arthritis and lupus treatment. rs10181656 lies in intron 3 of STAT4 and is the sentinel tagging SNP of the primary STAT4 risk haplotype for systemic lupus erythematosus — the variant that yielded the strongest statistical signal in a landmark Swedish fine-mapping study²² the strongest statistical signal in a landmark Swedish fine-mapping study
OR 1.71, 95% CI 1.40–2.08, P = 7.1 × 10⁻⁸; 485 SLE patients vs 563 controls.

The Mechanism

rs10181656 is in nearly perfect linkage disequilibrium with rs7574865 (r² ≈ 1.0), meaning both SNPs tag the same intron-3 haplotype block. The shared risk haplotype drives elevated STAT4 mRNA and protein expression³³ elevated STAT4 mRNA and protein expression
Risk haplotype cells produce significantly more STAT4 in mesenchymal tissues; overexpression correlates with anti-dsDNA antibody production, a hallmark of severe lupus. Carriers of the G risk allele therefore generate an amplified STAT4 response when type I interferons or IL-12 engage their T cells and NK cells — producing exaggerated IFN-gamma output and driving the "interferon signature" that characterizes active lupus in approximately 75% of SLE patients.

The specific value of rs10181656 as a distinct catalog entry is that it was the directly-genotyped sentinel in two studies with findings not captured elsewhere: the Swedish haplotype over-expression paper⁴⁴ Swedish haplotype over-expression paper
Study found this specific SNP pair, not rs7574865, represented all the observed association signal in their haplotype model and, more critically, the cerebrovascular risk study by Svenungsson et al.⁵⁵ cerebrovascular risk study by Svenungsson et al.
Two independent SLE cohorts, n=424 + 154; directly genotyped rs10181656(G) as the exposure variable.

The Evidence

The Löfgren et al. 2008 haplotype study⁶⁶ Löfgren et al. 2008 haplotype study
485 SLE patients, 563 controls; 53 STAT4 SNPs tested; rs10181656 and rs7582694 in perfect LD; OR 1.71 (1.40–2.08); P = 7.1×10⁻⁸; risk haplotype frequency 0.24 in cases vs 0.17 in controls identified rs10181656 as the strongest intra-locus signal from STAT4. Crucially, this risk haplotype was over-expressed in primary human mesenchymal cells and correlated with anti-dsDNA antibody production — establishing a molecular connection between the haplotype and lupus pathophysiology.

The most clinically striking finding comes from the Svenungsson et al. 2010 cerebrovascular study⁷⁷ Svenungsson et al. 2010 cerebrovascular study
Two SLE cohorts (n=424 and n=154); all Swedish; occurrence of ischemic cerebrovascular disease, ischemic heart disease, and venous thromboembolism documented; rs10181656(G) directly tested: G allele carriers with SLE had an OR of 2.3 (95% CI 1.6–3.3) for ischemic cerebrovascular disease — a magnitude "comparable to hypertension" as a stroke risk factor. The proposed mechanism runs through antiphospholipid antibody (aPL) accumulation: G allele carriers showed OR 1.6 (95% CI 1.2–2.0) for carrying two or more aPL types. Antiphospholipid antibodies promote platelet activation and thrombus formation in cerebral vessels, providing the mechanistic bridge from STAT4-amplified immune activation to stroke.

An independent Finnish SLE family cohort using transmission disequilibrium testing⁸⁸ Finnish SLE family cohort using transmission disequilibrium testing
TDT avoids population stratification artifacts; rs10181656 strongest intron-3 signal; p=0.001, OR 2.53 replicated the association. The intron-3 haplotype containing rs10181656 has also been associated with rheumatoid arthritis in Chinese Han and Korean cohorts⁹⁹ rheumatoid arthritis in Chinese Han and Korean cohorts
rs10181656 directly genotyped in Northwestern Chinese Han; also replicated in Korean RA cohorts, and with RA in an Iranian population (p=0.007), though notably the RA association does not replicate in African-Americans — consistent with a haplotype that is rarer in African-ancestry populations (~15% G allele frequency vs ~22% in Europeans).

Practical Actions

CG heterozygotes carry one copy of the STAT4 risk haplotype and face approximately 60–70% elevated SLE risk relative to CC homozygotes. Familiarizing yourself with lupus early warning signs and seeking prompt antinuclear antibody (ANA) testing if symptoms develop is appropriate monitoring given this background risk. GG homozygotes carry two copies of the risk haplotype, conferring more than doubled SLE risk (OR ~2.9 by dose-response extrapolation) and particularly elevated risk for the ischemic cerebrovascular complications documented in the Svenungsson study. For GG carriers, proactive baseline autoantibody testing and antiphospholipid antibody assessment provides important clinical context before symptoms emerge. If SLE is diagnosed in any G allele carrier, the STAT4-amplified JAK-STAT pathway (directly targeted by tofacitinib, baricitinib, and upadacitinib) may represent a particularly relevant therapeutic axis.

Interactions

rs10181656 and rs7574865 are in near-perfect linkage disequilibrium (r² ≈ 1.0) and tag the same STAT4 intron-3 risk haplotype. Users who have both SNPs genotyped will see consistent results across both entries — CG at rs10181656 corresponds to GT at rs7574865. The companion SNP rs10488631 (IRF5) operates upstream in the interferon production pathway, and its risk allele acts additively with the STAT4 haplotype to amplify total SLE susceptibility. CFB rs1270942 participates in the same lupus genetic architecture through the alternative complement pathway and further stratifies renal involvement risk. A compound action covering the combined STAT4 + IRF5 risk burden is proposed below (interaction candidate).